Global Genitourinary Drugs Market Share Is Likely To Reach At A CAGR Value Of Around 3.47% By 2030

11-Jan-2023 | Facts and Factors

According to Facts and Factors, the global genitourinary drugs market size was worth around USD 32 billion in 2021 and is predicted to grow to around USD 68.51 billion by 2030 with a compound annual growth rate (CAGR) of roughly 3.47% between 2022 and 2030.

Genitourinary drugs are used for the treatment of diseases related to the reproductive organs and the urinary system. These organs are developed from the intermediate mesoderm and the reproductive system is also known as the genital system. It is made of anatomical organs that involve sexual reproduction. Other non-living substances like hormones, fluids, and pheromones are also termed important accessories in the reproductive system.

Browse the full “Genitourinary Drugs Market Size, Share, Growth Analysis Report By Product (Hormonal Therapy, Urological, and Others), By Disease (Erectile Dysfunction, Urinary Tract Infections, Hematuria, and Others), By End-User (Super Specialty Clinics, Hospitals, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022–2030" report at https://www.fnfresearch.com/genitourinary-drugs-market

Some of the most common types of concerns found in the women population include endometriosis which directly impacts the uterus of the woman. Other concerns like uterine fibroids, gynecological cancer, HIV / AIDS, interstitial cystitis, polycystic ovary syndrome, sexually transmitted diseases, and sexual violence are treated using genitourinary drugs. Male reproductive organs may suffer from diseases like erectile dysfunction, penis disorders, genital warts, circumcision, genital herpes, and gonorrhea. Urinary system medical concerns that can be cured using genitourinary drugs along with other subscription drugs include cases of kidney stones, urinalysis, ostomy, bladder cancer, and urinary incontinence.

The global genitourinary drugs market is projected to grow owing to the increasing research & development of effective and versatile drugs that can efficiently cure diseases related to reproductive organs and urinary systems. The greatest advancements are currently being made in the treatment of prostate cancer which starts and spreads across the male reproductive organ. It is one of the leading forms of cancer in men and has a high fatality rate. However, the growing number of United States Food and Drugs Administration approval as well as ongoing phase-wise research of newer drugs is projected to help the global market witness high CAGR.

Various multinational corporations are working in collaboration with pharmaceutical giants to enter remote markets and cater to a larger section of the population. These efforts will help the global market players expand their consumer database which in turn is projected to positively impact the global market sales value. The healthcare sector across regions is witnessing a surge in the number of investments since healthcare infrastructure is a leading indicator of economic growth and one of the key essentials for any economy to compete with the superpowers. Most of the investments are directed toward research activities. The increasing number of collaborative research is another contributing factor to the global market growth trajectory.

However, there may be certain growth restrictions in the coming years owing to the potential side effects associated with the use of genitourinary drugs. As these medicines are high in power, they should only be consumed under prescription by authorized medical professionals. Long-term exposure to drugs in untapped conditions can lead to severe health side effects which have already been observed in various cases. Other factors like consulting accurate and ethical trial processes may also act as a barrier during the global market growth as companies may fail to follow the laid down protocols to avoid non-approval from regulatory bodies.

A growing number of reproduction-related medical assistance may provide growth opportunities while the presence of counterfeit products is projected to challenge market growth.

Segmental Overview

The global genitourinary drugs market is segmented based on product, disease, end-user, and region

Based on disease, the global market divisions are erectile dysfunction, urinary tract infections, hematuria, and others. The global market was led by the other segment in 2021 in which treatment for prostate cancer led the segmental growth owing to growing interest and research toward finding a cure for the disease. A lot of the patients suffering from this type of cancer succumb to the disease without any show of symptoms and hence it is important to conduct extensive research and spread awareness amongst the men population about the disease. Prostate cancer is the 4th most common type of tumor that is detected across the globe.

Based on end-user, the global market divisions are super specialty clinics, hospitals, and others. Although doctors generally recommend critical cases to specialty clinics because they have more expertise, the hospital segment dominated the global market growth in 2021. Hospitals are responsible for providing primary care and only if the case is extremely rare, the cases are moved to specialty units. Urinary tract infection is known to affect nearly 3% of the global men population.

Regional Overview

North America is anticipated to lead the global genitourinary drugs market owing to the presence of some of the biggest brands in the pharmaceutical industry including Pfizer and Johnsons and Johnsons. The companies invest heavily in developing new products by adopting advanced technologies and techniques which is expected to propel the regional market growth. Asia-Pacific is anticipated to register a high CAGR due to the growing population and a subsequent number of medical cases. Increasing accessibility for the treatment of diseases associated with reproductive systems may help generate higher revenue. As estimated, around 18% of couples in Japan underwent infertility treatment or testing in 2021.

Report Scope

Competitive Analysis

The global genitourinary drugs market is dominated by players like Eli Lilly and Company, AstraZeneca, Ionis Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., and others.

Recent Developments:

• In January 2021, The US FDA approved the use of Relugolix to treat advanced prostate cancer. The new drug is expected to provide immediate results
• In November 2021, FDA approved Fetroja for the treatment of urinary tract infections

The global genitourinary drugs market is segmented as follows:

By Product 

• Hormonal Therapy
• Urological
• Others

By Disease 

• Erectile Dysfunction
• Urinary Tract Infections
• Hematuria
• Others

By End-User 

• Super Specialty Clinics
• Hospitals
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com